Ajanta Pharma Ltd. - Research Center
532331 AJANTPHARM Group (A) BSE data
Add to watchlist
| Results | |
| Statement |
Balance sheet
|
| More |
Balance sheet
(Rs crore)
| Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | Mar ' 18 | |
|---|---|---|---|---|---|
| Sources of funds | |||||
| Owner's fund | |||||
| Equity share capital | 17.17 | 17.39 | 17.54 | 17.54 | 17.69 |
| Share application money | - | - | 0.47 | 1.10 | - |
| Preference share capital | - | - | - | - | - |
| Reserves & surplus | 3,152.01 | 2,867.59 | 2,443.29 | 2,123.44 | 1,913.81 |
| Loan funds | |||||
| Secured loans | - | - | - | - | - |
| Unsecured loans | - | - | - | - | - |
| Total | 3,169.18 | 2,884.98 | 2,461.30 | 2,142.08 | 1,931.50 |
| Uses of funds | |||||
| Fixed assets | |||||
| Gross block | 2,113.52 | 2,048.20 | 1,900.81 | 1,545.55 | 1,356.37 |
| Less : revaluation reserve | - | - | - | - | - |
| Less : accumulated depreciation | 621.20 | 529.41 | 451.49 | 383.52 | 319.68 |
| Net block | 1,492.32 | 1,518.79 | 1,449.32 | 1,162.03 | 1,036.69 |
| Capital work-in-progress | 152.86 | 108.19 | 131.06 | 261.29 | 61.33 |
| Investments | 164.85 | 156.88 | 85.77 | 83.00 | 200.64 |
| Net current assets | |||||
| Current assets, loans & advances | 1,970.46 | 1,748.20 | 1,383.00 | 1,015.19 | 993.19 |
| Less : current liabilities & provisions | 611.31 | 647.08 | 587.85 | 379.43 | 360.35 |
| Total net current assets | 1,359.15 | 1,101.12 | 795.15 | 635.76 | 632.84 |
| Miscellaneous expenses not written | - | - | - | - | - |
| Total | 3,169.18 | 2,884.98 | 2,461.30 | 2,142.08 | 1,931.50 |
| Notes: | |||||
| Book value of unquoted investments | 42.99 | 17.89 | 70.43 | 46.03 | 200.64 |
| Market value of quoted investments | 121.86 | 138.99 | 15.34 | 36.97 | - |
| Contingent liabilities | 76.44 | 168.98 | 182.41 | 306.30 | 173.65 |
| Number of equity sharesoutstanding (Lacs) | 854.16 | 865.32 | 872.61 | 872.54 | 880.15 |
Mutual Fund Selector
Find the fund that is right for you
© 2022 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis